Newsroom

BRISBANE, Australia--(BUSINESS WIRE)--Megaport Limited (ASX: MP1) (“Megaport”), una plataforma líder mundial de infraestructura automatizada, acaba de anunciar el lanzamiento de sus servicios en Portugal, ampliando así su presencia en Europa y permitiendo que las empresas y los proveedores de servicios de la región se conecten al instante con los principales proveedores de nube, redes y centros de datos del mundo. Gracias a los nuevos puntos de conexión en Lisboa, los clientes de Portugal ahora...

MANHASSET, N.Y.--(BUSINESS WIRE)--The life-altering power of bioelectronic medicine took center stage this week as Northwell Health’s Feinstein Institutes for Medical Research hosted its seventh Bioelectronic Medicine Summit on September 28-29, 2026, at The Lighthouse at Chelsea Piers in New York City. The sold-out international scientific symposium, co-chaired by Eric H. Chang, PhD, associate professor in the Institute of Bioelectronic Medicine at the Feinstein Institutes and Christopher Puleo...

LONDON--(BUSINESS WIRE)--  Re: ERM FUNDING PLC.   GBP 100.00   MATURING: 31-Dec-2099   ISIN: XS2351471060     PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 15-Jul-2026 TO 15-Oct-2026 HAS BEEN FIXED AT 0.00 PCT   DAY BASIS: ACTUAL/365(FIX)   INTEREST PAYABLE VALUE 15-Oct-2026 WILL AMOUNT TO: GBP .0 PER GBP 100.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Xtrackers (IE) plc Investment Company with Variable Capital Registered Office: 78 Sir John Rogerson's Quay, Dublin 2, Ireland Registration number: 393802 (the “Company”) NOTICE TO SHAREHOLDERS OF THE SUB-FUNDS LISTED ON THE LONDON STOCK EXCHANGE Dublin, 09 October 2026 This announcement is to inform the shareholders of the sub-funds listed in the table below (each a Sub-Fund, and together the Sub-Funds) (the Shareholders) on behalf of the board of directors of the Com...

SHENZHEN, China--(BUSINESS WIRE)--Chipscreen Biosciences announced that China NMPA has approved the IND application for CS43158 tablets, a new molecular entity for the treatment of AML...

中国深圳--(BUSINESS WIRE)--(美国商业资讯)-- 深圳微芯生物科技股份有限公司（以下简称“微芯生物”，股票代码：688321.SH）宣布，公司自主研发的用于治疗急性髓系白血病（AML）的1类创新药CS43158片临床试验申请已获国家药品监督管理局批准。 AML是成人最常见的急性白血病，具有高度异质性，治疗难度大、复发率高。其中，FLT3突变作为关键驱动因素，在复发/难治性（R/R）患者中的发生率高达35%-45%。尽管FLT3抑制剂已在许多地区获批上市，但其单药疗效仍面临瓶颈：客观缓解率（ORR）约30%-40%，中位无进展生存期（mPFS）仅2-6个月，且60%-80%的患者会在6-12个月内因旁路激活、二次突变及克隆演化而产生耐药。因此，开发能同步阻断驱动突变与多重耐药旁路的新一代药物，被认为是突破现有治疗瓶颈的关键方向。 CS43158是微芯生物依托AI+化学基因组学平台自主研发、具有全球专利保护的多靶点蛋白激酶抑制剂。其采用差异化的多靶点协同抑制策略，在全面抑制FLT3（ITD/TKD等）驱动活性的同时，精准干预多条耐药旁路。该药对FLT3野生型过表达、FLT...

GALASHIELS, Schottland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, eine hundertprozentige Tochtergesellschaft der Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), gab heute die endgültigen Ergebnisse der deutschen MINT-Studie bekannt, in der Mogamulizumab bei Patienten mit Mycosis fungoides (MF) und dem Sézary-Syndrom (SS) untersucht wurde. Die Ergebnisse, die auf der Jahrestagung 2026 der Cutaneous Lymphoma Tumour Group (EORTC-CLTG) der Europäischen Organisation für Krebsf...

GALASHIELS, Scozia, e MARLOW, Inghilterra--(BUSINESS WIRE)--Kyowa Kirin International plc, una sussidiaria controllata al 100% da Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), oggi ha annunciato i risultati finali dello studio MINT condotto in Germania per la valutazione di mogamulizumab nei pazienti affetti da micosi fungoide (MF) e dalla sindrome di Sézary (SS). Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono...

GALASHIELS, Schotland & MARLOW, Engeland--(BUSINESS WIRE)--Kyowa Kirin International plc, een dochteronderneming volledig in handen van Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), maakte vandaag de definitieve resultaten bekend uit de Duitse MINT-studie ter beoordeling van mogamulizumab bij patiënten met mycosis fungoides (MF) en sézarysyndroom (SS). Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met...

ST HELIER, Jersey--(BUSINESS WIRE)--DPC Holdings (NYSE: DPC) (“Doncasters”) has agreed to dispose of the Ivostud business to Lenbach Equity Opportunities III. GmbH & Co. KG, a private equity fund advised by DUBAG Group, subject to any required approvals and customary closing conditions, with completion expected during Q4 2026. Ivostud is a non-material asset held for sale.Caution Concerning Forward-Looking StatementsThis press release contains forward-looking statements. Statements included...